Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• TCR Modified T Cell Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• TCR-Like Antibody Services
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• Bispecific TCR Development
• Drug Discovery for Cytokine Release Syndrome (CRS) Management
• Dendritic Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
• Other Services
  • HLA Typing Service
  • KIR Typing Service
  • Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19
  • Screening for COVID-19 T-cell Peptides and Immune Monitoring with MHC Tetramers

Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells

Cancer Vaccine is medicinal agent which can be utilized to elicit a natural immune response by enhancing T cell responses or increasing antibody production. With breath of experience and knowledge in the area of cancer vaccine, Creative Biolabs is dedicated to helping our clients successfully initiate and complete critical phases of cancer vaccine product discovery and development. Now we provide engineered human primary blood dendritic cells to induce antitumor cytotoxic lymphocytes to facilitate your immunotherapy projects.

• The Best Helper to Accelerate and Innovate Your Immuno-Cell Therapy
• The Most Valuable Cooperator for Developing the Best Candidate to Boost Your Project

Our Scientific Inspiration

As one of the current most popular immunotherapies, dendritic cell-based immunotherapy has shown its strength by boosting the patients’ own immune system to destroy cancer. DC-based immunotherapy has achieved significant clinical benefits, while some technical hurdles (including DC preparation, activation, cancer/testis antigen delivery) exist which limit its broad applications. Long Wu’s team has reported an influential study about “induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells”. They reported the development of immortalized and constitutively activated human primary blood dendritic cell lines (ihv-DCs). ihv-DCs can induce the generation of CTA-specific cytotoxic T lymphocytes (CTLs). These cytotoxic lymphocytes show the efficacy of lung metastasis suppression in NSG mice (see Fig.1). This approach can facilitate the development of cell-based immunotherapy to treat lung cancer.

Fig.1 Suppression of metastatic lung cancer by ihv-DC1.2-MAGEA3-primed cytotoxic lymphocytes in NSG mice. (Wu, 2018)

Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells

Inspired by this approach, our scientists developed a series of assays to facilitate your dendritic cell-based immunotherapy projects. Any individual module or integrated solution are all available.

• Development of human primary blood dendritic cell lines (ihv-DC cell lines);
• Expression of TLRs, cytokines, and cellular signaling molecules in ihv-DCs;
• Induction of tumor-associated antigen-specific CTLs by ihv-DCs;
• Anti-cancer efficacy evaluation by ihv-DC primed cytotoxic lymphocytes in mice models.

This approach shows several major significances as follows:

• Primary blood DCs are expanded at unlimited amounts;
• The DCs are constitutively activated and readily available to prime naïve T lymphocytes;
• The DCs can be genetically modified to present specific tumor antigens, and induce the generation of antigen-specific T and NK cells in high efficiency;
• The produced cytotoxic T and NK cells can suppress tumor growth and cancer metastasis in cancer mouse models.

Why Choose Creative Biolabs

It’s important for you to collaborate with a reliable and experienced partner to provide insights and suggestions, guide the right choice, eliminate the unsuccessful programs as early as possible. With our knowledge of dendritic cell and cancer vaccine, Creative Biolabs can assist in selecting the most promising candidate and guide our clients to develop better dendritic cell-based immunotherapies.

Highlight Features

• Guarantees accompanied in every step to reduce risks;
• A wide range of assays to cover all your needs to get promising candidate with good properties;
• State-of-the-art equipment is provided to ensure efficient manners;
• Intellectual property is our clients’ ownership;
• Strong support is our promise by our highly skilled technicians.

With rich laboratory capabilities and extensive immunotherapy experience, Creative Biolabs is fully confident in compliant data delivery within the desired timelines, and our client-focused, collaborative approach will ensure our clients can return us their additional needs at any stage without any hesitation. If you are interested in our services, please don’t hesitate to contact us to learn how we can be involved in your project.

Reference

1. Wu, Long, et al. "Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells." Proceedings of the National Academy of Sciences 115.19 (2018): E4453-E4462